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To explore the use of automated planning in robotic radiosurgery of benign vestibular
schwannoma (VS) tumors for dose reduction outside the planning target volume (PTV) to
potentially reduce risk of secondary tumor induction.
Methods
A system for automated planning (AUTOplans) for VS patients was set up. The goal of
AUTO- planning was to reduce the dose bath, including the occurrence of high dose spikes
leaking from the PTV into normal tissues, without worsening PTV coverage, OAR doses, or
treatment time. For 20 VS patients treated with 1x12 Gy, the AUTOplan was compared with
the plan generated with conventional, manual trial-and-error planning (MANplan).
Results
With equal PTV coverage, AUTOplans showed clinically negligible differences with MAN-
plans in OAR sparing (largest mean difference for all OARs: ΔD2% = 0.2 Gy). AUTOplan
dose distributions were more compact: mean/maximum reductions of 23.6/53.8% and 9.6/
28.5% in patient volumes receiving more than 1 or 6 Gy, respectively (p<0.001). AUTOplans
also showed smaller dose spikes with mean/maximum reductions of 22.8/37.2% and 14.2/
40.4% in D2% for shells at 1 and 7 cm distance from the PTV, respectively (p<0.001).
Conclusion
Automated planning for benign VS tumors highly outperformed manual planning with
respect to the dose bath outside the PTV, without deteriorating PTV coverage or OAR spar-
ing, or significantly increasing treatment time.
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Introduction
Stereotactic radiosurgery is an increasingly used option for management of patients with
benign vestibular schwannoma (VS) tumors [1–5]. However, an increased risk of secondary
tumor formation associated with radiation exposure is well established [6–10]. Therefore, in
radiotherapy, dose outside the planning target volume (PTV) should be avoided as much as
possible, especially for patients with a long life expectancy.
High delivery accuracy can be obtained with the robotic system due to real-time image-
guided tracking, allowing small PTV margins [11, 12], and non-coplanar treatment [13].
Currently, treatment plans in radiotherapy are generally generated in an interactive trial-
and-error process in which the planner tries to steer the treatment planning system (TPS)
towards generation of an acceptable solution (“manual planning”). This may be a time con-
suming process and the resulting plan quality may heavily depend on the skills and experience
of the planner and on the available planning time and software. The potential of automated
treatment planning for both enhancement of plan quality and drastic reduction in planning
time, as alternative to manual planning, has been shown in many studies [14–23].
However, the existing literature on automated planning is focused on reduction of high
doses in OARs or enhancement of PTV dose. To the best of our knowledge, this is the first
study focusing on the use of automated planning for overall reduction of dose bath. The study
was inspired by observing the inability, in manual planning, to optimally reduce the dose bath,
and the planning time investment in getting a possible improvement, as systematically tried.
In our institution, a system for fully automated, multi-criterial treatment plan generation
has been developed, including optimization of beam directions. For this study, this system was
used as a pre-optimizer for the clinical TPS, that comes with the robotic treatment unit to
automatically generate deliverable plans for VS patients (AUTOplan). We investigated
whether automated planning could reduce the dose bath compared to manually generated
plans (MANplan), while not deteriorating dose delivery to the PTV or OARs, and keeping
treatment times comparable.
Materials and methods
Patients and manual planning (MANplan)
Contoured CT scans of 20 vestibular schwannoma patients, previously treated at our depart-
ment with the CyberKnife (CK) robotic treatment unit (Accuray Inc, Sunnyvale, USA), were
included in the study. All patient-related information was fully anonymized prior conducting
the research. According to the regulations of the Ethics Committee of Erasmus MC no ethical
approval for this retrospective study was needed as there was no impact on treatment and the
applied patient data.
The gross tumor volume (GTV) was defined as the volume of contrast enhancement on the
T1-weighted MRI, after CT/MRI fusion. No margins were applied for planning (GTV = PTV).
The average tumor size was 2.9 cc (1.0-7.3 cc). Delineated OARs were brainstem, trigeminal
nerves, area of virtual facial nerve, optic nerves, chiasm, cochlea (when clinically relevant),
pituitary gland, and eyes.
For planning, tumor coverage (>98% of the volume receiving 100% of the prescribed dose)
had highest priority, while strictly fulfilling OAR Dmax constraints and high dose conformal-
ity around the target. Furthermore, the goal was to maximally reduce the dose bath, including
minimizing dose spikes. Various planning strategies were clinically used to control this dose
spillage, based on planners’ preferences and experience. All MANplans were generated in Mul-
tiplan [24] clinical TPS (Accuray Inc, Sunnyvale, USA) that comes with the CK, with the Iris
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variable aperture collimator [25], avoiding diameters smaller than 10 mm and larger than 40
mm. CK full head node path was used for a total 179 non-coplanar available beam directions.
Patients were treated with a single fraction of 12 Gy, prescribed at the 80% isodose.
Automated planning (AUTOplan)
Clinically deliverable CK plans for VS patients were generated in a two-step process:
1. For each patient, a pre-plan was automatically generated with the in-house developed Eras-
mus-iCycle TPS [20, 21, 23, 26]. Plan generation with Erasmus-iCycle is driven by a so-
called wish-list, describing all planning constraints and objectives. The latter have ascribed
priorities for steering the multi-criterial plan generation, resulting in clinically favorable
trade-offs between all treatment objectives. Generated plans are Pareto-optimal. For this
study, a wish-list was made for VS plan generation, minimizing dose spillage from the PTV
while not deteriorating PTV and OAR dose, or substantially increasing the treatment time.
Erasmus-iCycle and wish-list building have been extensively described in the literature
[13, 20].
2. The Erasmus-iCycle plan generated in step i was used to automatically create a patient-spe-
cific planning template for subsequent automatic plan generation by the clinical TPS Multi-
plan. The planning template contained the planning constraints to ensure generation in
Multiplan of a clinically deliverable plan that mimicked the original Erasmus-iCycle plan.
This two-step approach was developed as for practical and regulatory reasons Erasmus-
iCycle cannot be used directly for clinical plan delivery.
A similar two-step approach is currently clinically used at Erasmus MC for automated
VMAT planning for prostate cancer, head and neck cancer, cervical cancer, and advanced
lung cancer, using the Monaco clinical TPS (Elekta AB, Stockholm, Sweden) in the second
step [21]. A distinct difference between VS autoplanning for robotic treatment and automated
VMAT planning is the inclusion of non-coplanar beam-angle selection for VS.
All generated AUTOplans were based on the same planning protocol, the same choice from
Iris collimators, node set, and the same dose prescription as used for clinical MANplan genera-
tion (above).
To minimize dose spillage in AUTOplans, the template for automated planning with Multi-
plan (step ii above) contained individualized Dmax constraints for shells at distances of 1, 3,
and 5 cm from the PTV. For each patient, these shell constraints were obtained from the Eras-
mus-iCycle plan, generated in step i. In Erasmus-iCycle, the maximum doses at these shells
were minimized, while respecting all hard planning constraints and the (higher) priorities for
adequate PTV coverage and OAR sparing. AUTOplan generation in Multiplan in step ii was
performed in high resolution with intensive treatment time reduction.
Automated planning with fixed shell constraints
As described above, individually optimized shell constraints, derived from the Erasmus-iCycle
plan, were used in the second step of AUTOplan generation with the Multiplan TPS. In an
additional analysis, we investigated whether it was possible to use for all patients the same
Dmax constraints instead of patient-specific values. This study was performed to understand
how patient-specific constraints impact plan quality, keeping all other parameters the same,
or, opposite, to see if it was possible to use equal values for all patients without losing in plan
quality.
For each shell, the population-fixed constraint was calculated as the average of the patient-
specific Dmax values found in the Erasmus-iCycle plans of the 20 study patients. Then, for
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each of the patients, a second AUTOplan was generated, using the fixed constraints. In the
remainder of the paper, the second AUTOplans with fixed constraints are referred to as
fAUTOplans.
Plan comparisons
Prior to comparisons of AUTOplans with MANplans and fAUTOplans with AUTOplans all
plans were rescaled to a tumor V12Gy of 98%, when achieved (in line with the clinical plan-
ning protocol). Plans were compared using OAR near-maximum doses, D2%, conformity
index (CI), and treatment time. To evaluate dose bath and spikes, patient volumes VD with D
up to 10 Gy were assessed, as well as D2%, of shells from 1 to 7 cm away from the tumor, for
spillage. Two-sided Wilcoxon signed-rank tests were used to analyze plan differences, using
p<0.05 for statistical significance.
Results
AUTOplan vs. MANplan
All MAN- and AUTOplans were clinically acceptable with tumor coverage >98% (98.3±0.1%)
while fulfilling all OAR constraints (Table 1). Treatment times were comparable; 36.1±5.0 min
and 38.2±4.1 (p = 0.008) for MAN- and AUTOplans, respectively, allowing plan comparison
without unacceptable treatment time difference bias.
CIs for AUTOplans (1.16±0.06) were slightly better than for MANplans (1.18±0.09), but
the difference was not significant (p = 0.4).
As for PTV coverage, MAN- and AUTOplans were comparable in terms of OARs sparing.
For all OARs, the mean difference in near-maximum dose was below 0.2 Gy and statistically
not significant. Only the brainstem Dmean was on average slightly lower for the AUTOplans,
which was statistically significant, 2.2±0.7 Gy vs. 2.4±0.8 Gy, p = 0.02.
Dose bath was substantially reduced in the AUTOplans (see Fig 1 for example). Both
patient volumes receiving dose and dose spikes were reduced with autoplanning compared to
manual planning. For most patients, volumes VD receiving more than D Gy were smaller in
the AUTOplans, as visible in the upper panel of Fig 2 and Table 1. Population-average percent-
age VD reductions for D = 1, 2, 3, 6, 8, and 10 Gy were 23.6%, 17.5%, 15.3%, 13.5%, 9.6%, 6.1%
and 2.9%, respectively (all p<0.005, apart from V10Gy with p = 0.06). AUTOplans also had
reduced near-maximum doses in the shells at 1, 2, 3, 5 and 7 cm from the PTV, mostly reflect-
ing smaller spikes and closer to the tumor. Average reductions of shell D2% with AUTOplans
were 22.8%, 20.5%, 16.8%, 16.7% and 14.2%, respectively (all p<0.001), as visible in the lower
panel of Fig 2 and Table 1.
AUTOplans used less MU (4899 vs. 5716) and nodes (56.1 vs. 66.6), but more beams (161.7
vs. 121.8), all p<0.004.
fAUTOplan vs. AUTOplan
Table 2 shows for each patient the Dmax for the shells at 1, 3, and 5 cm from the PTVs, as
obtained from plan optimization with Erasmus-iCycle, and used as individualized shell con-
straints in Multiplan optimization in the second phase of the AUTOplan generation. The pre-
sented population mean values were used for all the patients to generate the fAUTOplans.
Using population average shell constraints instead of the individualized constraints
(Table 2) for plan generation in Multiplan (fAUTOplan) resulted in an unacceptable PTV cov-
erage for 5 out of 20 patients (Table 2, patients 14, 16, 18, 19 and 20), with a minimum of
92.3% instead of 98%, due to too tight shell constraints.
Dose bath reduction for benign tumor through robotic autoplanning
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For the remainder of the patients, with equal PTV coverage, there were no statistically sig-
nificant differences between fAUTOplans and AUTOplans in CI, mean and near-maximum
OAR doses, patient volumes VD receiving more than D Gy (D�10 Gy), and D2% at shells
from 1-7 cm from the PTV.
Discussion
Several studies have observed superiority of automated plan generation compared to conven-
tional, interactive trial-and-error planning regarding enhancement of PTV dose, or reduction
of OAR doses [14, 16, 21, 26, 27]. Apart from plan quality advantages, automated planning did
always result in drastic reductions in planning workload.
Especially for patients with a long life expectancy, such as VS patients, dose outside the
PTV should be maximally avoided to reduce the risk for secondary tumor induction. To the
best of our knowledge, this is the first paper on automated planning that primarily aims at the
overall reduction of low and high doses outside the PTV of a benign tumor. To this purpose, a
Table 1. For all 20 patients, mean values for automatically generated plans (AUTOplans) and manually generated (MANplans). Bold values represent the statistically
significant differences as p<0.05 with the Wilcoxon’s signed-rank test.�CI = Conformity Index.
AUTOplans MANplans
Mean ± SD Mean ± SD
PTV V12Gy 98.3 ± 0.1 98.3 ± 0.1 %
CI� 1.2 ± 0.1 1.2 ± 0.1
Brainstem D2% 9.7 ± 1.5 9.8 ± 1.4 Gy
Dmean 2.2 ± 0.6 2.4 ± 0.8 Gy
Trigeminal Nerve D2% 11.7 ± 1.0 11.8 ± 0.8 Gy
Facial Nerve D2% 14.0 ± 0.2 14.0 ± 0.3 Gy
L Optic Nerve D2% 0.1 ± 0.0 0.2 ± 0.1 Gy
R Optic Nerve D2% 0.1 ± 0.0 0.2 ± 0.1 Gy
Chiasm D2% 0.3 ± 0.1 0.3 ± 0.1 Gy
Cochlea D2% 11.6 ± 1.2 11.8 ± 1.1 Gy
Pituitary D2% 0.3 ± 0.1 0.4 ± 0.1 Gy
L Eye D2% 0.1 ± 0.0 0.1 ± 0.0 Gy
R Eye D2% 0.1 ± 0.0 0.1 ± 0.0 Gy
Patient V1Gy 271.2 ± 142.9 347.6 ± 162.5 cc
V2Gy 68.0 ± 32.2 84.7 ± 44.8 cc
V3Gy 36.2 ± 16.6 44.0 ± 22.9 cc
V4Gy 24.1 ± 10.9 28.8 ± 14.9 cc
V6Gy 14.3 ± 6.5 16.2 ± 8.3 cc
V8Gy 9.6 ± 4.6 10.3 ± 5.3 cc
V10Gy 6.2 ± 3.3 6.4 ± 3.4 cc
PTV Shell 1cm D2% 3.7 ± 0.5 4.9 ± 0.8 Gy
PTV Shell 2cm D2% 2.0 ± 0.4 2.6 ± 0.5 Gy
PTV Shell 3cm D2% 1.4 ± 0.3 1.7 ± 0.3 Gy
PTV Shell 5cm D2% 1.0 ± 0.2 1.2 ± 0.2 Gy
PTV Shell 7cm D2% 0.8 ± 0.2 1.0 ± 0.2 Gy
Treatment Time 38.2 ± 4.0 36.1 ± 4.8 min
MU 4899 ± 704 5716 ± 996
Nodes 56.1 ± 10.8 66.6 ± 21.1
Beams 161.8 ± 24.2 121.8 ± 29.6
https://doi.org/10.1371/journal.pone.0210279.t001
Dose bath reduction for benign tumor through robotic autoplanning
PLOS ONE | https://doi.org/10.1371/journal.pone.0210279 February 6, 2019 5 / 10
Fig 1. Axial dose distributions for an example patient. The AUTOplan (right) shows a reduced dose bath, with also smaller dose spikes, than
the MANplan (left). Reduction in brainstem dose is also visible. (Red contour = PTV, pink contour = Brainstem).
https://doi.org/10.1371/journal.pone.0210279.g001
Fig 2. Differences between AUTOplans and MANplans in dose spillage. Positive differences reflect higher quality for the AUTOplan. Upper
panel: differences in patient volumes receiving more than 1, 2, 3, . . ., 10 Gy. Lower panel: differences in D2% for shells at 1, 2, . . ., 7 cm away
from the tumor. For the individual patients, differences were calculated as (MANplan − AUTOplan)/MANplan � 100. The last column shows
population mean differences and their statistical significance marked with � (p<0.05).
https://doi.org/10.1371/journal.pone.0210279.g002
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system was set up and configured for fully automated non-coplanar plan generation for
robotic stereotactic treatment of VS patients.
The project was started after observing frequent problems with controlling or improving
dose bath and spikes from the PTV in manual planning (see Fig 1a). In this study we have
demonstrated that automated planning could reduce the dose bath, without worsening PTV
coverage or OAR sparing, or substantially increasing treatment time. Moreover, due to the
automation, there was no workload in the plan generation.
As explained in the M&M section, final AUTOplans were generated with the commercial
TPS that comes with the robotic treatment unit. Therefore, this TPS is indeed able to generate
highly compact plans, with minimal dose delivery outside the PTV and avoiding dose spikes.
In the autoplanning procedure, the individualized shell constraints, used in the commercial
TPS to maximally avoid dose spillage, were automatically generated using a pre-optimization
with our in-house developed multi-criteria optimizer (step i, M&M section). In conventional
manual planning, shell constraints are defined for each patient in a trial-and-error procedure.
Then, finding the optimal constraint values for individual patients is often impractical, because
it is too time consuming to be feasible in clinical routine.
The presented workflow for AUTOplan generation of highly compact dose distributions is
likely to be applicable also for other benign tumors, which will be a topic for further research.
To the best of our knowledge, this is the first study to systematically investigate a possible
reduction in dose bath while mantaining treatment technique. Integral dose reduction is a
reported outcome from many plan comparison studies [28–31], beside the OARs evaluation,
as well as different metrics have been proposed [32, 33], reflecting the clinical relevance.
Table 2. For each patient, Dmax values for shells at 1, 3 and 5 cm from the PTV as derived from the Erasmus-
iCycle plan, and population mean values with standard deviations. Patient-specific Dmax values were used as con-









Pt 1 427 156 112
Pt 2 374 140 106
Pt 3 430 157 117
Pt 4 423 173 138
Pt 5 458 171 133
Pt 6 426 155 120
Pt 7 428 168 129
Pt 8 370 146 98
Pt 9 390 123 88
Pt 10 344 108 74
Pt 11 423 170 105
Pt 12 417 174 137
Pt 13 368 135 107
Pt 14 475 181 124
Pt 15 357 119 84
Pt 16 536 210 162
Pt 17 396 165 123
Pt 18 471 198 167
Pt 19 522 181 134
Pt 20 486 200 149
Mean±SD 426±53 162±27 120±25
https://doi.org/10.1371/journal.pone.0210279.t002
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However a systematic dose bath reduction can not be easily investigated without a consistent
planning work flow such as the one used in this study, including the dose bath improvement
without loosing quality in the PTV and OAR dose distributions.
For 5/20 patients, the applied population-based, fixed shell constraints used for generating
the fAUTOplan were too tight, resulting in an unacceptably low PTV coverage. No correlation
with PTV size or other features was found. For the other 15 patients, the fAUTOplan was simi-
lar in quality as the AUTOplan. This does however not necessarily imply that in clinical rou-
tine, acceptable high quality plans would have been generated for the latter patients, using the
fixed constraints. fAUTOplans were generated with an automated planning workflow and it is
uncertain whether using the population-based constraints with manual planning would have
resulted in high quality plans for these 15 patients. This could have been dependent on the
complexity of the individual cases and on the skills of the involved planners. Anyway, com-
pared with automated planning, the workload would have increased.
On the longer term and to serve the radiotherapy community, there is a clear need for more
advanced commercial treatment planning systems that are faster and/or facilitate automated
plan generation.
Conclusion
Compared to conventional planning, automated plan generation for robotic treatment of
patients with a benign vestibular schwannoma tumor could to a large extent reduce low to
high dose outside the PTV while maintaining acceptable tumor coverage and similar OAR
dose, and keeping delivery time comparable.
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